About Ablatus Therapeutics
Ablatus Therapeutics is a company based in Cambridge (United Kingdom) founded in 2015 by David Brooks. It operates as a B2B. Ablatus Therapeutics has raised $5.69 million across 7 funding rounds from investors including Gov.uk, NVM Private Equity and Turquoise. The company has 3 employees as of January 31, 2022. Ablatus Therapeutics operates in a competitive market with competitors including Novocure, QV Bioelectronics, Mirai Medical, Autem Therapeutics and Pulse Biosciences, among others.
- Headquarter Cambridge, United Kingdom
- Employees 3 as on 31 Jan, 2022
- Founders David Brooks
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ablatus Therapeutics Limited
- Date of Incorporation 07 Oct, 2015
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.69 M (USD)
in 7 rounds
-
Latest Funding Round
$189.17 K (USD), Series A
Mar 11, 2024
-
Investors
Gov.uk
& 6 more
-
Employee Count
3
as on Jan 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ablatus Therapeutics
Ablatus Therapeutics has successfully raised a total of $5.69M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $189.17 thousand completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series A — $189,169
-
First Round
First Round
(10 Feb 2016)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series A - Ablatus Therapeutics | Valuation |
investors |
|
| Jun, 2021 | Amount | Series A - Ablatus Therapeutics | Valuation | Turquoise | |
| Aug, 2020 | Amount | Grant - Ablatus Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ablatus Therapeutics
Ablatus Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, NVM Private Equity and Turquoise. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Turquoise is engaged in financial advisory and investment for climate technologies.
|
Founded Year | Domain | Location | |
|
Private equity investments are managed across the UK.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ablatus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ablatus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ablatus Therapeutics Comparisons
Competitors of Ablatus Therapeutics
Ablatus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novocure, QV Bioelectronics, Mirai Medical, Autem Therapeutics and Pulse Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for solid tumors are developed via Tumor Treating Fields.
|
|
| domain | founded_year | HQ Location |
Electrotherapy devices for brain tumor treatment are manufactured.
|
|
| domain | founded_year | HQ Location |
Mirai Medical is focused on transforming gastrointestinal disease treatment.
|
|
| domain | founded_year | HQ Location |
Bioelectric platforms for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Nano-Pulse Electro-Signaling technology is developed for targeted cellular disruption.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ablatus Therapeutics
Frequently Asked Questions about Ablatus Therapeutics
When was Ablatus Therapeutics founded?
Ablatus Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Ablatus Therapeutics located?
Ablatus Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Ablatus Therapeutics?
David Brooks is the current CEO of Ablatus Therapeutics. They have also founded this company.
Is Ablatus Therapeutics a funded company?
Ablatus Therapeutics is a funded company, having raised a total of $5.69M across 7 funding rounds to date. The company's 1st funding round was a Grant of $1.79M, raised on Feb 10, 2016.
How many employees does Ablatus Therapeutics have?
As of Jan 31, 2022, the latest employee count at Ablatus Therapeutics is 3.
What does Ablatus Therapeutics do?
Ablatus Therapeutics, established in 2015, excels in providing healthcare solutions, developing medical devices, surgical equipment, and ablation technology. Develops innovative devices for bimodal electric tissue ablation. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Who are the top competitors of Ablatus Therapeutics?
Ablatus Therapeutics's top competitors include Novocure, QV Bioelectronics and Pulse Biosciences.
Who are Ablatus Therapeutics's investors?
Ablatus Therapeutics has 7 investors. Key investors include Gov.uk, NVM Private Equity, Turquoise, Turquoise, and Low Carbon Innovation Fund.
What is Ablatus Therapeutics's valuation?
The valuation of Ablatus Therapeutics is $5.3M as of May 2018.